Value added medicines: what value repurposed medicines might bring to society?

by Mondher Toumi, Cécile Rémuzat
Published 2017-01-01

Gene therapies development: slow progress and promising prospect

by Eve Hanna, Cécile Rémuzat, Pascal Auquier, Mondher Toumi
Published 2017-01-01

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines

by Krzysztof Lach, Michal Dziwisz, Cécile Rémuzat, Mondher Toumi
Published 2017-01-01

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry

by Karolina Badora, Aleksandra Caban, Cécile Rémuzat, Claude Dussart, Mondher Toumi
Published 2017-01-01

Key drivers for market penetration of biosimilars in Europe

by Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi
Published 2017-01-01

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

by Mondher Toumi, Anastasiia Motrunich, Aurélie Millier, Cécile Rémuzat, Christos Chouaid, Bruno Falissard, Samuel Aballéa
Published 2017-01-01

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states

by Cécile Rémuzat, Anna Kapuśniak, Aleksandra Caban, Dan Ionescu, Guerric Radière, Cyril Mendoza, Mondher Toumi
Published 2017-01-01